NCT07299695Toboroz3. fázis
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Evaluating the Efficacy of Intravenous Immunoglobulin in Patients Hospitalized for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. márc. 16.
Rövid összefoglaló (regiszter, angolul)
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events. Inflammation and immune system imbalance are thought to play an important role in causing AE-IPF. Early clinical experience suggests that intravenous immunoglobulin (IVIG) can be beneficial for patients suffering from AE-IPF. This clinical trial aims to determine whether adding IVIG to usual treatment can improve outcomes for patients hospitalized with AE-IPF.
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 3. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 196 (tervezett)
- Első benyújtás
- 2025. nov. 26.
- Kezdés
- 2026. jan. 25.
- Elsődleges befejezés
- 2028. jún.
- Fő szponzor
- Argyrios Tzouvelekis
- Betegségek
- Idiopátiás tüdőfibrózis
- NCT-szám
- NCT07299695
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 3. fázis
- Tervezett résztvevők: 196
- 2026. jan. 25. és az elsődleges befejezés (2028. jún.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Patients with active malignancy or currently receiving cancer treatment, except for basal cell or squamous cell skin cancer or low-risk prostate cancer (T1 or T2a stage with PSA <10 ng/dL). These criteria are aligned with current guidelines.
- Patients that have received treatment for >14 days within the preceding month with >20mg daily prednisone (or equivalent) or any treatment during the last month with immunosuppressants (e.g., cyclophosphamide, mycophenolate etc.) according to already published therapeutic protocols or > 1 mg/kg/d from more than 7 days in the last 15 days.
Más betegség
- Patients with acute worsening due to uncontrolled heart failure or pulmonary embolism.
- Patients with known hypersensitivity to corticosteroids, IVIG or any component of the study treatment.
Laborértékek
- Patients with known IgA deficiency (IgA level <7 mg/dL)- to preclude IVIG reactions.
- Patients without a definite diagnosis of IPF or AE-IPF based on clinical, radiological, laboratory evaluation, and multidisciplinary discussion.
Egyéb
- Patients participating to another interventional clinical trial.
- Patients with documented pregnancy or lactation.
- Patients under tutorship or curatorship.
- Patients deprived of liberty or under court protection.
- Patients who refuse to participate or decline to provide written informed consent.
Kiket keres a vizsgálat
- Patients ≥ 18 years of age
- Patients with IPF diagnosis that fulfils ATS/ERS Consensus Criteria.
- Patients hospitalised with a definite or suspected AE-IPF diagnosis, as defined by the international working group criteria and as ascertained by the responsible Primary Investigator.
- The criteria of IPF-AE are as follows:
- Previous or concurrent diagnosis of IPF
- Acute worsening or development of dyspnoea typically < 1 month duration
- Computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia pattern
- Deterioration not fully explained by cardiac failure or fluid overload Patients who fail to meet all 4 criteria due to missing computed tomography should be considered as having "suspected Acute Exacerbation".
- If the diagnosis of IPF is not previously established, this criterion can be met by the presence of radiologic and/or histopathologic changes consistent with usual interstitial pneumonia pattern on the current evaluation.
- If no previous computed tomography is available, the qualifier "new" can be dropped from the third AE-IPF criterion.
- Patient able to understand and sign a written informed consent form. In case of incapacity of the patient, the written informed consent form will be signed by the patients' legally authorized representative.
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Department of Respiratory Medicine, University Hospital of Patras | Pátrai | Görögország | Toboroz |
Kapcsolódó publikációk
- Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis.Front Immunol · 2026 · PMID 42164489
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.